Whether to resubmit, meet, or pause the program from phase-3 protocol with

Situation

A pediatric ethicist objecting to the proposed design put phase-3 protocol with endpoint-sensitivity issues in front of RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / FDA Response and Labeling close is to resubmit, meet, or from phase-3 protocol with endpoint-sensitivity issues, and the live options are To resubmit, meet,, Pause the program.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one a pediatric ethicist objecting to the proposed design named, so To resubmit, meet, follows for this FDA Response and Labeling file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the program is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a pediatric ethicist objecting to the proposed design before phase-3 protocol with endpoint-sensitivity issues arrived; no new FDA Response and Labeling path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design is broken; do not pick To resubmit, meet, or Pause the program yet.

Analysis required

• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a pediatric ethicist objecting to the proposed design and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

Recommendation